|
|
Article: Zomig(R) Nasal Spray Now Available to Consumers; - Welcome News to the 62 Percent of Female Migraine Sufferers Who Want Fast-Acting Pain Relief, According to a New National Survey(1) -.
- Article from:
- PR Newswire
- Article date:
- October 1, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
AstraZeneca today announced the launch of ZOMIG(R) (zolmitriptan) Nasal Spray (5.0, 2.5, 1.0, 0.5 mg) as a fast-acting treatment option(2) for the 28 million Americans who suffer from migraine.(3) Approved by the U.S. Food and Drug Administration (FDA) on October 1 for the acute treatment of migraine with or without aura in adults, ZOMIG Nasal Spray provides migraine relief as early as 15 minutes and increasing efficacy up to two hours.(2) That attribute is an important consideration for migraine sufferers, as indicated in a new national survey -- conducted by the American Council for Headache Education (ACHE) and AstraZeneca -- in which 62 percent of female migraineurs ...